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Doxorubicin-encapsulating liposomal formulations, known as Doxil, have been used for the treatment
of Kaposi’s sarcoma and ovarian cancer. However, there is still a need for a drug delivery system for
doxorubicin that limits the treatment’s side effects, namely, mucositis and hand-and-foot syndrome.
The AG73 peptide derived from the laminin a1 chain is a ligand for syndecans, and syndecan-2 is highly
expressed in some cancer cells. In this study, to develop a safer and more selective liposomal
formulation, we prepared doxorubicin-encapsulating AG73 peptide-modiﬁed liposomes (AG73–Dox).
First, we assessed the selectivity of AG73–Dox for cancer cells, including syndecan-2 over-expressing
cells, using ﬂow cytometry and confocal microscopy. AG73–Dox showed selective cellular uptake on
cancer cells and enhancement of the intracellular uptake. Next, we examined the cytotoxicity of AG73–
Dox using a WST assay. AG73–Dox exhibited a higher cytotoxicity against cancer cells than other
control liposomes. In addition, we showed that the antitumor efﬁcacy of AG73–Dox in vivo was better
than that of free Dox. When we examined the biodistribution of liposomes, AG73 peptide-modiﬁed
liposomes (AG73-L) tended to bind to intratumoral vessels and extravasated in the tumor tissue. Thus,
further optimization of AG73-L toward tumor targeting may lead to a development of a useful tool for
cancer therapy.
& 2011 Elsevier B.V. All rights reserved.1. Introduction
The anthracycline anticancer drug doxorubicin (Dox) is gen-
erally used in chemotherapy for the treatment of various tumors,
including breast cancer, leukemia, and soft-tissue sarcoma. Var-
ious mechanisms explain its therapeutic effect [22]. These
mechanisms include DNA intercalation, lipid peroxidation, and
inhibition of topoisomerase II. However, the use of free Dox is
rather limited due to its severe side effects, including cardiotoxi-
city, hair loss, and nephrotoxicity [10,20,22,30]. Dox has been
encapsulated in liposomes to reduce these problems associated
with free Dox treatment [23]. Liposomes have been explored as a
potential drug delivery carrier. Compared with the free drug,
liposomal-encapsulated drugs typically exhibit a prolonged sys-
temic circulation time and increased tumor localization by the
enhanced permeability and retention (EPR) effect [15]. In addition,ll rights reserved.
.
.
.the toxicity of the liposomally encapsulated anticancer drugs
could be diminished, as the drug cannot exert its activity when
encapsulated in liposomes during bloodstream circulation [11,31].
In 1995, the liposomal Dox formulations Doxil and Caelyx were
approved by the FDA for the treatment of AIDS-related Kaposi’s
sarcoma and ovarian cancer. Although Doxil strongly reduced the
cardiotoxicity of Dox in clinical trials, other side effects arose.
Several patients suffered from mucositis and hand-and-foot syn-
drome due to the localization of the liposomes in skin capillaries
[22]. Therefore, to develop safer and more selective liposomal
formulations, many research groups have tried to develop tumor-
targeting liposomes using transferrin, folic acid, RGD peptide, or
antibodies as ligands [6,14,21,27–29].
The present study focused on AG73, which is a 12-amino-acid
synthetic peptide derived from the globular domain of the
laminin a1 chain. AG73 peptide is a ligand for syndecans, one of
the major heparan sulfate-containing transmembrane proteogly-
cans [3,8,24]. Moreover, syndecan-2 is highly expressed in various
cancer cell lines ([7,26,32]. Therefore, we tried to develop Dox-
encapsulating AG73 peptide-modiﬁed liposomes (AG73–Dox) as
novel tumor-targeting liposomes to enhance the intracellular
uptake of anticancer drugs and treatment efﬁcacy.
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selectivity of AG73–Dox for cancer cells, including syndecan-2
over-expressing cells. Furthermore, we examined the antitumor
effects of AG73–Dox in vitro and in vivo.2. Materials and methods
2.1. Materials
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dis-
tearoylphosphatidylethanolamine-methoxy-polyethyleneglycol
(DSPE–PEG2000–OMe), and 1,2-distearoyl-sn-glycero-3-phosphati-
dylethanolamine–polyethyleneglycol–maleimide (DSPE–PEG2000–
Mal) were purchased from NOF Corporation (Tokyo, Japan).
Doxorubicin (Dox) was purchased from SIGMA-Aldrich Co. (St. Louis,
MO, USA). For cell culture, Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) was purchased from Kohjin Bio Co., Ltd. (Tokyo, Japan).
Fetal bovine serum (FBS) was purchased from Equitech Bio Inc.
(Kerrville, TX, USA). All other materials were used without further
puriﬁcation.
2.2. Preparation of liposomes
Liposomes composed of DSPC and DSPE–PEG2000–OMe at a
molar ratio of 94:6 were prepared by a reverse-phase evaporation
method. In brief, all reagents were dissolved in 1:1 (v/v) chloroform/
diisopropylether. Three hundred millimolar citrate buffer (pH 4.0)
was then added to the lipid solution, and the mixture was sonicated
and evaporated at 65 1C. The organic solvent was completely
removed, and the size of the liposomes was adjusted to approxi-
mately 150 nm using extruding equipment and sizing ﬁlters (pore
sizes: 100 and 200 nm, Nuclepore Track-Etch Membrane, Whatman
plc, UK). For the ﬂuorescent labeling of the lipid membrane,
1,1-dioctadecyl-3,3,3,3-tetramethyl-indocarbocyanine perchlorate
(DiI) was also added (1 mol% of total lipids). After the sizing, the
liposomes were passed through a 0.45-mm pore-size ﬁlter (Syringe
ﬁlter, ASAHI TECHNOGLASS Co., Chiba, Japan) for sterilization.
2.3. Preparation of Dox-encapsulating liposomes
The Dox-encapsulating liposomes were prepared by a remote
loading method with a pH gradient [4,19]. In brief, liposomes were
passed through a Sephadex G-50 (GE Healthcare UK Ltd., Buck-
inghamshire, England) spin column that was equilibrated with N-[2-
hydroxyethyl]piperazine-NV-[2-ethanesulfonic acid] (HEPES)-buf-
fered saline (HBS; 20 mMHEPES, 150 mMNaCl, pH 7.5) to exchange
the external buffer. The eluted liposomes had a transmembrane pH
gradient with pH 4.0 inside and pH 7.5 outside the liposomes. The
eluted liposomes were incubated with Dox (at a Dox:lipid molar
ratio of 1:5) at 65 1C for 30 min. To remove the unencapsulated Dox,
the mixture was passed through a Sephadex G-50 spin column. The
Dox-encapsulating liposomes were stored at 4 1C until use. The lipid
concentration was measured using Phospholipid C test Wako (Wako
Pure Chemical Industries, Ltd., Osaka, Japan), and the Dox concen-
tration was determined by measuring the absorbance at 480 nm
(Inﬁnite M1000, TECAN, Ma¨nnedorf, Switzerland) in a 1% Triton
X-100 solution and comparing the absorbance value to the standard
curve. The encapsulated efﬁciency was calculated according to the
following equation:
Encapsulated efficiencyð%Þ ¼ ½ðD=LÞ30 min=½ðD=LÞinitial  100
where (D/L)30 min is the ratio of Dox to lipid concentration after the
liposomes were passed through the Sephadex G-50 spin column and
(D/L)initial is the ratio of Dox to lipid at the initial concentration.2.4. Preparation of Dox-encapsulating AG73 peptide-modiﬁed
liposomes
The Cys–AG73 peptide (CGG–RKRLQVQLSIRT) and a scrambled
Cys–AG73T control peptide (CGG–LQQRRSVLRTKI) were synthe-
sized manually using the 9-ﬂuorenylmethoxycarbonyl (Fmoc)-
based solid-phase strategy and were prepared in the COOH
terminal amide form and puriﬁed by reverse-phase high-perfor-
mance liquid chromatography. Dox-encapsulating liposomes
composed of DSPC, DSPE–PEG2000–OMe, and DSPE–PEG2000–Mal
at a molar ratio of 94:4:2 were prepared by a reverse-phase
evaporation method and a remote loading method. For coupling,
AG73 peptide at a molar ratio of 2-fold DSPE–PEG2000–Mal was
added to the Dox-encapsulating liposomes, and the mixture
was incubated for 24 h at 4 1C to conjugate the cysteine of the
Cys–AG73 peptide with the maleimide of the Dox-encapsulating
liposomes using a thioether bond. The resulting AG73 peptide-
conjugated Dox-encapsulating liposomes (AG73–Dox) were
passed through a Sephadex G-50 spin column to remove any
excess peptide. AG73–Dox was modiﬁed with 6 mol% PEG and
2 mol% peptides. The particle size and zeta potential of the
liposomes were measured using NICOMP 380 ZLS (Particle Sizing
Systems, Santa Barbara, CA, USA).
2.5. Cell lines and animals
293T human embryonic kidney carcinoma cells that stably
overexpressed syndecan-2 (293T-Syn2) and murine colorectal
carcinoma cells (colon26) were cultured in DMEM that was
supplemented with 10% FBS, penicillin (100 U/ml), streptomycin
(100 mg/ml), and puromycin (0.4 or 100 mg/ml) at 37 1C in a
humidiﬁed 5% CO2 atmosphere.
Male BALB/c mice (6 weeks old) were purchased from Tokyo
Laboratory Animals Science Co., Ltd. (Tokyo, Japan). Animal use
and relevant experimental procedures were approved by the
Tokyo University of Pharmacy and Life Science Committee on
the Care and Use of Laboratory Animals.
2.6. Flow cytometry analysis for the intracellular uptake
of Dox-encapsulating AG73 peptide-modiﬁed liposomes
The intracellular uptake of liposomes was determined by ﬂow
cytometry analysis [9]. 293T-Syn2 cells (1105 cells/well) were
seeded in a 24-well plate and incubated for 48 h at 37 1C in
5% CO2. Colon26 cells (5104 cells/well) were also seeded in a
24-well plate and incubated for 24 h at 37 1C in 5% CO2. The
medium was then replaced with Dox-encapsulating liposomes
(Dox–PEG), AG73–Dox, or Dox-encapsulating AG73T peptide-
modiﬁed liposomes (AG73T–Dox) that were diluted with culture
medium for a ﬁnal Dox concentration of 20 mg/ml. The plates
were incubated for 1 h at 37 1C. The medium was removed;
subsequently, each cancer cell line was washed with phosphate-
buffered saline (PBS), and the cell samples were examined by ﬂow
cytometry using an FACScan (Becton Dickinson, San Jose, CA,
USA). Cell-associated Dox was excited with an argon laser
(488 nm). Data were collected in 10,000 gated events and ana-
lyzed with the CELL Quest software program.
2.7. Confocal microscopy analysis
293T-Syn2 cells (2 or 5104 cells/well) were seeded in a
24-well plate and incubated for 48 h at 37 1C in 5% CO2. Colon26
cells (5104 cells/well) were also seeded in a 24-well plate and
incubated for 24 h at 37 1C in 5% CO2. Then, the medium was
replaced with Dox–PEG, AG73–Dox, AG73T–Dox, or free Dox
diluted with culture medium for a ﬁnal Dox concentration of
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medium was removed, and subsequently, each cancer cell line
was washed with PBS and then ﬁxed with 4% paraformaldehyde
for 1 h at 4 1C (293T-Syn2) or for 15 min at room temperature
(colon26). For nuclear staining, the cells were treated with DAPI
for 1 h. Fluorescence images of the cells were analyzed using an
FV1000-D confocal microscope (OLYMPUS, Tokyo, Japan).
2.8. Cytotoxicity studies
The cytotoxicity of liposomes was determined using the WST
assay. 293T-Syn2 and colon26 suspensions (1104 cells/well for
293T-syn2 and 3103 cells/well for colon26) were added to Dox–
PEG, AG73–Dox, AG73T–Dox, or free Dox with a serial concentra-
tion of Dox ([Dox]¼1–40 mg/ml). Then, the suspension was
incubated for 4 h at 37 1C in 5% CO2. After 4 h of incubation at
37 1C, the cells were washed, and fresh DMEM was added. The
cells were then seeded in a 96-well plate and incubated for 48 h
at 37 1C in 5% CO2. After incubation, 10 mL of the cell-counting
solution (WST-8, Dojindo Laboratories, Tokyo, Japan) was added
to each well and was incubated for 2 h (293T-Syn2) or 1 h
(colon26) at 37 1C in 5% CO2. Cell viability was assessed by
measuring the absorbance at 450 nm with a reference absorbance
at 650 nm (Inﬁnite M1000, TECAN, Ma¨nnedorf, Switzerland). Cell
viability was calculated according to the following formula:
Cell viabilityð%Þ ¼ A450ðsampleblankÞ=A450ðcontrolblankÞ  100:
2.9. In vivo antitumor efﬁcacy
Colon26 cells (1106 cells/mouse) were inoculated subcuta-
neously in the right ﬂank of mice. Five days after tumor inocula-
tion (when the tumor volume reached approximately 50 mm3),
HBS buffer used as a vehicle (control), Dox, Dox–PEG, or AG73–
Dox was administered via a tail vein of the mice (n¼4). The
injected dose of Dox in each administration was 2 mg/kg
(approximately 10 mmol/kg dose of lipid). Various formulations
were given every other day for a total of 5 doses. The size of
tumors and the body weight of each mouse were monitored, andTable 1
Size and z potential of Dox-encapsulating peptide-modiﬁed liposomes.
Liposomes Mean diameter (nm)7S.D. z potential (mV)7S.D.
Dox–PEG 131.776.4 0.5270.16
AG73–Dox 161.5714.8 0.3270.20
AG73T–Dox 134.676.3 0.3770.36
Fig. 1. Size distribution of Dox-encapsulating peptide-modiﬁed liposomes obtained uthe tumor volume was calculated using the following equation:
Tumor volume ðmm3Þ ¼ longer diameter ðshorter oneÞ2  0:5
2.10. Intratumoral localization and biodistribution of liposomes
Colon26 cells (1106 cells/mouse) were inoculated subcuta-
neously in the right ﬂank of mice. Seven days after tumor inoculation
(when the tumor volume reached approximately 100–200 mm3),
DiI-labeled liposomes (lipid concentration: 10 mmol/kg) were
administered via a tail vein of the mice (n¼6). At 6 h after injection
of the liposomes, the mice were sacriﬁced, and the tumors and
organ tissues (heart, spleen, liver, and kidney) were dissected.
These tissues were ﬁxed in 10% paraformaldehyde substituted with
20% sucrose and then embedded in optimal cutting temperature
compound (Sakura Finetech, Co., Ltd., Tokyo, Japan) and frozen at
80 1C. Each tumor and organ tissue section was prepared with a
width of 10 mm and mounted on a poly-L-lysine coated slide. For
immunohistochemistry, the tumor section was blocked with 10%
lapine serum in TBS for 30 min at 4 1C and incubated with anti-
mouse CD31 antibody (BD Pharmingen) overnight at 4 1C. Subse-
quently, the section was incubated with Alexa Fluor 488 rabbit
anti-rat IgG (Molecular Probes) for 1 h at room temperature. Each
tumor and organ section was then mounted with VECTASHIELD
Hard Set Medium with DAPI (VECTOR LABORATORIES, INC, USA)
and ﬂuorescently observed with BZ-8100 (KEYENCE, Japan).3. Results and discussion
3.1. Characteristics of Dox-encapsulating AG73 peptide-modiﬁed
liposomes
First, we sought to prepare Dox-encapsulating AG73 peptide-
modiﬁed liposomes (AG73–Dox). As shown in Table 1, the mean
particle diameter of Dox–PEG, AG73–Dox, or AG73T–Dox ranged
from 130 to 170 nm with a relatively narrow distribution (Fig. 1).
The zeta potential of the Dox-encapsulating liposomes was slightly
negative in value. The efﬁciency for the remote loading of Dox into
the liposomes was 90–95% with a drug/lipid ratio of 1:5 (molar
ratio). The encapsulated efﬁciency also remained unchanged even in
the case of peptide modiﬁcation. After one month of storage at 4 1C,
the encapsulated efﬁciency was less than 5%.
3.2. Cellular uptake of Dox-encapsulating AG73 peptide-modiﬁed
liposomes
To examine the selective cellular uptake of Dox transfected by
liposomes via the syndecan-2 receptor, the amount of Dox uptakesing DLS: Size distribution of Dox–PEG (A), AG73–Dox (B), and AG73T–Dox (C).
Y. Negishi et al. / Results in Pharma Sciences 1 (2011) 68–75 71into cancer cells including syndecan-2 overexpressing cells was
evaluated by ﬂow cytometry analysis. As shown in Fig. 2, the
cellular uptake of AG73–Dox on both 293T-Syn2 and colon26 was
higher than that of Dox–PEG or AG73T–Dox. The laminin-derived
AG73 peptide is known as a ligand for syndecans, and it has been
reported that syndecan-2 is highly expressed in various cancer
cells [3,5,8,24,26]. In addition, the AG73 peptide has been shown
to bind to the heparin sulfate side chains of syndecan [8]. There-
fore, to verify that AG73–Dox can bind to syndecan-2 on the
surface of cancer cells, the cancer cells were treated with AG73–
Dox and heparin (Fig. 3). Our data showed that the cellular uptake
of AG73–Dox was down-regulated by the treatment with heparin.
However, the cellular uptake of Dox–PEG or AG73T–Dox was not
down-regulated by the treatment (data not shown). Therefore,
these results suggested that AG73–Dox could effectively target
cancer cells via the syndecan-2 receptor.3.3. Intracellular localization of Dox-encapsulating AG73 peptide-
modiﬁed liposomes using confocal laser scanning microscopy
To further elucidate the intracellular uptake of Dox, the intracel-
lular localization of Dox was evaluated after the treatment of cells
with Dox–PEG, AG73–Dox, AG73T–Dox, or free Dox using confocal
microscopy. As shown in Fig. 4, the cells treated with AG73–DoxFig. 2. Cellular uptake of Dox-encapsulating peptide-modiﬁed liposomes on the cance
The cells were treated with Dox-encapsulating liposomes (PEG–Dox), Dox-encapsulatin
([Dox]¼20 mg/ml) for 1 h at 37 1C. After incubation, the cells were washed, and their ﬂ
Fig. 3. Effect of heparin on cellular uptake activity of AG73–PEG on the cancer cells 29
The cells were treated with AG73–PEG ([Dox]¼20 mg/ml) and heparin (10 mg/ml) or o
ﬂuorescence intensities were measured by ﬂow cytometry.showed a strong red ﬂuorescence, whereas cells treated with
Dox–PEG or AG73T–Dox showed a faint red ﬂuorescence. The
intracellular localization of Dox in the cells treated with AG73–Dox
could be observed on the surface of the cell membrane and in
the cytoplasm with a slight colocalization in the nuclei. However,
these localizations after the treatment with AG73–Dox were blocked
by heparin. A punctuated pattern could also be detected in the
cytoplasm of both cancer cells (indicated by white arrows in Fig. 4),
which suggested that the Dox localized in the endosomes [12]. Thus,
these results suggested that AG73–Dox could enhance the intracel-
lular uptake of Dox compared with Dox–PEG or AG73T–Dox.3.4. Cytotoxicity of Dox-encapsulating AG73 peptide-modiﬁed
liposomes
To examine the therapeutic efﬁciency of AG73–Dox, the cyto-
toxicity of Dox-encapsulating liposomes against cancer cells was
evaluated using a WST assay. The cytotoxicity studies were initially
performed with empty liposomes on the cancer cells to determine
whether the liposomes themselves contributed to the cytotoxicity.
The concentration of lipids tested was matched to the amount of
lipids used in the drug-encapsulating formulations. At the concen-
tration of lipids used, the cell viability was more than 80% that of
the control (data not shown). These data indicated that the emptyr cells 293T-Syn2 (A) and colon26 (B).
g AG73 peptides (AG73–Dox), or AG73T peptide-modiﬁed liposomes (AG73T–Dox)
uorescence intensities were measured by ﬂow cytometry.
3T-Syn2 (A) and colon26 (B).
nly AG73–Dox for 1 h at 37 1C. After incubation, the cells were washed, and their
Fig. 4. Confocal microscopy images of 293T-Syn2 (A and C) and colon26 (B and D) cells incubated with PEG–Dox, AG73–Dox, AG73T–Dox, or free Dox ([Dox]¼10 mg/ml:
293T-Syn2, 20 mg/ml: colon26) for 4 h at 37 1C.
After incubation, the cells were washed and ﬁxed. The cells were then treated with DAPI (blue) for nuclear staining. Blue: ﬂuorescence of DAPI. Red: ﬂuorescence of Dox.
Pink: the merged blue and red that indicates the colocalization of DAPI and Dox. The arrows indicate that Dox localizes in the endosomes (C and D). Scale bars represent
20 mm.
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Fig. 5, the cell viability was dependent on the concentration of Dox.
Furthermore, the cytotoxicity of AG73–Dox was more sensitive than
that of Dox–PEG or AG73T–Dox against both types of cancer cells. In
particular, the cytotoxicity of AG73–Dox against 293T-Syn2 was
notably higher in comparison with that against colon26. This result
may be due to the fact that the ability and sensitivity of the
intracellular uptake of free Dox into the cancer cells were distinct
from those of 293T-Syn2 and colon26, as shown by confocal
microscopy (Fig. 4), as it has been reported that colon26 exhibits a
constitutive expression of mdr1a and mdr1b that encodes the drug
efﬂux transporter P-glycoprotein [16].
3.5. Intracellular drug delivery of Dox-encapsulating AG73 peptide-
modiﬁed liposomes
To understand the drug delivery and release behaviors
of AG73–Dox, the cells were washed after the treatment ofAG73–Dox and placed into fresh medium for further incubation
at 37 1C. They were imaged using confocal microscopy at various
time points after washing. As shown in Fig. 6, Dox was diffused
through the 293T-Syn2 in a time-dependent manner and then
was colocalized with the nuclei. This result could be due to the
release of Dox from AG73–Dox inside endosomes with a lower
pH. In addition, at 24 h post-incubation, we observed fragmenta-
tion of the nuclei, which is characteristic of apoptosis (indicated
by white arrows in Fig. 6). Moreover, at 48 h post-incubation, we
observed increased fragmentation of the nuclei. Therefore, these
results suggested that after the cellular uptake of AG73–Dox, Dox
was slowly released from AG73–Dox and was subsequently
transferred to nuclei, which led to cytotoxicity (Fig. 5).
3.6. In vivo antitumor efﬁcacy
Next, as AG73–Dox showed higher cellular uptake and cyto-
toxicity against cancer cells compared to Dox–PEG, the antitumor
Fig. 5. Cytotoxicity of Dox-encapsulating liposomes for 293T-Syn2 (A) or colon26 (B).
The cells were incubated with serial concentrations of Dox–PEG, AG73–Dox, AG73T–Dox, or free Dox for 4 h at 37 1C. After incubation, the cancer cells were washed, and
fresh medium was added. The cells were seeded and further incubated for 48 h at 37 1C before the WST assay. ypo0.05; zpo0.01; *po0.005. Data are represented as
mean7SD.
Fig. 6. Confocal microscopy images of 293T-Syn2 after incubation with AG73–
Dox. 293T-Syn2 (2105/well) were seeded in a 24-well plate.
293T-Syn2 cells after 4 h of incubation ([Dox]¼10 mg/ml) at 37 1C were washed
and transferred into fresh medium for further incubation. The confocal microscopy
images were taken after washing. The post-incubation times (0, 30 min, 2, 24, or
48 h) are also indicated above the ﬁgure. The cells were ﬁxed and treated with
DAPI (blue) for nuclear staining. Blue: ﬂuorescence of DAPI. Red: ﬂuorescence of
Dox. Pink: the merged blue and red that indicates the colocalization of DAPI and
Dox. The arrows indicate fragmentation of the nuclei. Scale bars represent 20 mm.
Fig. 7. In vivo antitumor effects of various treatments against tumors in tumor-
bearing mice (n¼4). (A) Tumor growth curves for tumor-bearing mice. (B) Changes
in body weight during the treatments.
The tumor-bearing mice were intravenously injected with HBS used as a vehicle
(control), free Dox, Dox–PEG, or AG73–Dox ([Dox]¼2 mg/kg) when the tumor
volume reached about 50 mm3 (5 days after tumor inoculation). The tumor volumes
and the body weights of the tumor-bearing mice were monitored. Each value is
presented as the average with SE. The arrows show the days of injection. Signiﬁcant
differences were found between the AG73–Dox and free Dox groups and are
marked as npo0.05.
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bearing mice at a dose of 2 mg Dox/kg body weight. As shown in
Fig. 7, the Dox–PEG group had suppressed tumor growth com-
pared with the free Dox group. These results showed that
liposomal doxorubicin may be diffused passively into the tumor
tissue by the EPR effect [15]. However, there was no signiﬁcantdifference between the Dox–PEG group and the free Dox group,
whereas the tumor growth inhibition efﬁcacy of the AG73–Dox
group was better than that of the free Dox group (Po0.05). When
the antitumor effect of Dox–PEG was compared with that of
AG73–Dox, there was no signiﬁcant difference in antitumor effect.
We also monitored the body weights of the tumor-bearing
mice to assess any side effects of AG73–Dox. The body weight
change during the tumor treatment was not observed in the
AG73–Dox group.
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To evaluate the targeting effect of AG73 peptide-modiﬁed
liposomes in vivo, we examined the intratumoral localization of
AG73 peptide-modiﬁed liposomes. As shown in Fig. 8, DiI-labeled
PEG liposomes (PEG-L), which did not contain Dox, were leaked
from intratumoral vessels and diffused in the tumor tissue,
whereas DiI-labeled AG73 peptide-modiﬁed liposomes (AG73-L)
were mainly bound to intratumoral vessels and were partially
extravasated in the tumor. The AG73 peptide is a ligand for
syndecan-2. Syndecan-2 is also highly expressed in human
vascular endothelial cells [17]. Moreover, the cellular uptake of
AG73–Dox in human umbilical vein endothelial cells was higher
than that of Dox–PEG or AG73T–Dox, which was observed using
ﬂow cytometry (data not shown). In this study, there is little
difference between antitumor effect of Dox–PEG and that of
AG73–Dox. However, it seems that AG73–Dox tend to target not
only tumor tissue but also intratumoral vessels (Figs. 7 and 8). To
assess whether AG73-L is tumor selectivity, we injected DiI-
labeled PEG-L or AG73-L and observed various other organs
(heart, liver, spleen, and kidney) using ﬂuorescence microscopy.
As shown in Fig. 9, although the ﬂuorescence intensity of AG73-L
was slightly high in the heart compared to that of PEG-L, there
was little difference between PEG-L and AG73-L in the other
organs.
Recently, to enhance the therapeutic effect of Dox, the drug
delivery ﬁeld has focused its attention on designing nanoparticles
that are capable of releasing a drug efﬁciently when exposed to a
speciﬁc triggering mechanism [1,2]. Such triggers include pH,
light, ultrasound, enzymatic action, and heat [13]. Among the
trigger-sensitive nanoparticle formulations that have been devel-
oped, ultrasound-sensitive liposomes (bubble liposomes) could
function as a novel gene delivery tool by exposure to ultrasound
[25,18]. Therefore, it is necessary to optimize the AG73–Dox for
in vivo application by changing the peptide modiﬁcation ratio or
PEG ratio. Furthermore, the combination of AG73–Dox withFig. 8. Localization of AG73 peptide-modiﬁed liposomes within the tumor.
The tumor-bearing mice (n¼6) were intravenously injected with DiI-labeled PEG-
liposomes (PEG-L) or DiI-labeled AG73 peptide-modiﬁed liposomes (AG73-L)
when the tumor volume reached 100–200 mm3 (7 days after tumor inoculation).
Liposomes were injected as lipids at a dose of 10 mmol/kg. At 6 h after injection,
each tumor was dissected, and the tumor sections were then prepared in slices
with widths of 10 mm each. Each section was stained with anti-CD31 antibody for
the labeling of the endothelial cells. Green: CD31. Red: ﬂuorescence of DiI. Yellow:
the merged green and red indicates the colocalization of liposomes at the site of
the vascular endothelial cells. Scale bars represent 50 mm.
Fig. 9. Biodistribution analysis by ﬂuorescence imaging.
The tumor-bearing mice (n¼6) were intravenously injected with PEG-L or AG73-L
(lipid concentration: 10 mmol/kg). At 6 h after injection, each tissue was dissected,
and sections were then prepared in slices with widths of 10 mm each. These
sections were observed using a ﬂuorescence microscope. Scale bars represent
50 mm.bubble liposomes and ultrasound may enable enhancement of
the therapeutic effect.4. Conclusion
In this study, doxorubicin-encapsulating AG73 peptide-mod-
iﬁed liposomes (AG73–Dox) were developed to increase the
intracellular uptake of anticancer drugs and to achieve an
improved therapeutic effect speciﬁcally against tumors. The
AG73 peptide is a very suitable tumor-targeting molecule because
it is known to be a ligand for syndecans, which are expressed in
various cancer cells. The intracellular uptake of AG73–Dox was
higher than that of control liposomes (PEG–Dox and AG73T–Dox).
Moreover, AG73–Dox exhibited cytotoxicity and antitumor effects
in vitro and in vivo. In addition, AG73 peptide-modiﬁed liposomes
intended to bind intratumoral vessels within the tumor. Thus,
further optimization of AG73-L toward tumor targeting may lead
to a development of a useful tool for cancer therapy.
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